Cited by 174Nutrition and Health in AgingPancreatic and Hepatic Oncology ResearchMuscle Physiology and Disorders

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review

Open access
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R.M., Lyadov, V.·2015·Pancreatology

Abstract

Background/objectives Cachexia affects ∼ 80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database until December 2013. After identifying relevant titles, abstracts were read and eligible articles data retrieved on preformatted sheets. The prevalence and impact of sarcopenia/cachexia on survival was evaluated. Results In total 1145 articles were retrieved, only 10 were eligible. Definitions of cachexia and sarcopenia were heterogeneous. In patients with normal weight (BMI 18.5-24.9 kg/m(2)) the prevalence of sarcopenia ranged from 29.7 to 65%. In overweight or obese patients (BMI >25 kg/m(2)) were 16.2%-67%. Sarcopenia alone was not demonstrated to be an independent factor of decreased survival, although obese sarcopenic patients were shown to have significantly worse survival in two studies. Conclusions Impact of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma is currently understudied in the available literature. Definitive association between cachexia and survival cannot be drawn from available studies, although weight loss and sarcopenic obesity might be considered as poor prognostic factors. Further prospective trials utilizing the consensus definition of cachexia and including other confounding factors are needed to investigate the impact of cachexia and sarcopenia on survival in pancreatic adenocarcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pan.2014.11.006

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sarcopenia and fat loss are known components of the wasting syndrome of pancreatic ductal adenocarcinoma and may have prognostic implications.

    “Indeed, sarcopenia and fat loss are known to be part of a wasting syndrome of pancreatic ductal adenocarcinoma and might have prognostic implications.117,118”

    From Early detection of pancreatic cancer (2020) · cites this paper as [117]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R. M., & Lyadov, V.
Affiliations
  • Lithuanian University of Health Sciences (LT)
  • Sorbonne Paris Cité (FR)
  • Freeman Hospital (GB)
  • Ministry of Health of the Russian Federation (RU)
Corresponding author
Lyadov, V.
Venue
Pancreatology
Publisher
Elsevier BV
Published
2015-01
Volume
15
Issue
1
Pages
19-24
ISSN
1424-3903 (ISSN-L)
OpenAlex
W2068101666
Cited by
174
References
34
Citations by year
2026: 7 · 2025: 7 · 2024: 15 · 2023: 13 · 2022: 25 · 2021: 25 · 2020: 14 · 2019: 22 · 2018: 17 · 2017: 10 · 2016: 13 · 2015: 6
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Pancreatology (publishedVersion)
  • PubMed (publishedVersion)
  • Lithuanian University of Health Sciences (submittedVersion)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
Educational and Research Program Pancreas 2000
Topics
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
cachexia, sarcopenia, pancreatic ductal adenocarcinoma, survival, skeletal muscle mass, sarcopenic obesity, weight loss, obesity, prognostic factors, inflammatory markers
MeSH terms
Cachexia, Humans, Pancreatic Neoplasms, Prognosis, Weight Loss, Prevalence, Survival Rate, Carcinoma, Pancreatic Ductal, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review